Medivir Interim Report 1 Jan. -- 30 Sep 2003

Huddinge, SWEDEN


HUDDINGE, Sweden, Oct. 23, 2003 (PRIMEZONE) -- In July, Medivir entered a licensing agreement with Boehringer Ingelheim (BI) on MIV-310.

- CCS group divested to the Segulah II L.P. investment fund as of 1 July 2003 for SEK 210 m.

- In July, Medivir entered a licensing agreement with the Population Council on MIV-150. Medivir's stock has been quoted on the Stockholm Exchange's Attract 40 list since 1 July.

- Medivir's net sales were SEK 148.2 (208.7)m, profit after tax stood at SEK 2.3 (-26.7)m and earnings per share amounted to SEK 0.27 (-3.16).


FOR MORE INFORMATION, PLEASE CONTACT: 
Rein Piir, CFO and VP IR, +46 8 5468 3123 or +46 (0)70 853 7292

This information was brought to you by Waymaker http://www.waymaker.net

The following files are available for download:

http://www.waymaker.net/bitonline/2003/10/23/20031023BIT00790/wkr0001.doc

The full report

http://www.waymaker.net/bitonline/2003/10/23/20031023BIT00790/wkr0002.pdf

The full report